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In vitro efficacy of hyperbaric oxygen therapy against
Leishmania tropica promastigotes and amastigotes
Özgür KORU1, Soykan ÖZKOÇ2, Kemal ŞİMŞEK3, Gürkan MERT4, Hakan AY3, Seray TÖZ5,
Mehmet TANYÜKSEL1

Aim: To assess the efficiency of hyperbaric oxygen (HBO) therapy on L. tropica, which is the major causative agent of
cutaneous leishmaniasis in Turkey.
Materials and methods: The effects of HBO on Leishmania tropica promastigote and amastigote forms were studied at a
pressure of 2.5 atmosphere absolute (ata). We examined the cytotoxic effect of HBO on promastigotes using the trypan
blue exclusion test and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye-reduction assay.
To investigate the effects of HBO treatment on the growth of the promastigotes, HBO-treated and non-HBO-treated cell
culture flasks were incubated at 26 °C for 3 days, while the effects of HBO on L. tropica amastigotes were detected using
the acridine orange staining method.
Results: We observed that the cytotoxic effect emerged after 2 h and reached a maximum at 6 h with both methods. The
number of live promastigotes was monitored for 24 h after treatment and there was a slight elevation at 2 h of treatment,
but significant suppression was seen after 4 and 6 h of treatment (P < 0.001). We detected that the effect of HBO on L.
tropica amastigote forms increased by 3.3%, 17.2%, and 38.5% at 2, 4, and 6 h, respectively.
Conclusion: The results presented here indicate that HBO treatment could be used as supportive therapy in association
with chemotherapeutic agents against L. tropica infection.
Key words: Hyperbaric oxygen, Leishmania tropica, cytotoxicity

Leishmania tropica amastigot ve promastigot formlarına karşı hiperbarik oksijen
tedavisinin in vitro etkinliği
Amaç: Bu çalışmanın amacı, Türkiye’de kutanöz leishmaniasisin en önemli etkeni L. tropica üzerinde HBO tedavisinin
etkinliğini değerlendirmektir.
Yöntem ve gereç: Leishmania tropica promastigot ve amastigot formları üzerinde hiperbarik oksijenin etkileri 2,5
atmosfer basıncı (ata) altında çalışıldı. HBO’nun promastigot formları üzerindeki sitotoksik etkileri, tripan mavisi
testi ve MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) yöntemiyle incelendi. HBO tedavisinin
L. tropica promastigot formları üzerinde etkilerini araştırmak amacıyla HBO uygulamasına maruz bırakılmış ve
bırakılmamış hücre kültür plakları 26oC’de üç gün boyunca inkübe edildi. Diğer taraftan HBO’nun L. tropica amastigot
formları üzerine olan etkileri akridin oranj boyama yöntemiyle tespit edildi.
Bulgular: Her iki yöntem ile sitotoksik etkinin iki saat sonra başladığı ve altı saat sonra en üst seviyeye ulaştığı
gözlemlendi. Canlı promastigotların sayısı tedaviden sonra 24 saat boyunca izlendi ve tedavinin ikinci saatinin sonunda
promastigot sayılarında hafif bir artış olduğu, dört ve altı saat sonrasında ise promastigot sayılarının artışında önemli bir
azalma olduğu tespit edildi (P < 0,001). Diğer taraftan HBO tedavisinin L. tropica amastigot formları üzerinde etkisinin
2, 4 ve 6. saatler için sırasıyla % 3,3, % 17,2 ve % 38,5 olduğu gözlemlendi.
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Sonuç: Bu çalışmada elde edilen sonuçlar, HBO tedavisinin L. tropica formlarına karşı kemoterapi ile birlikte destekleyici
tedavi olarak kullanılabileceğini göstermektedir.
Anahtar sözcükler: Hiperbarik oksijen, Leishmania tropica, sitotoksitite

Introduction
The leishmaniases are a group of parasitic diseases
caused by different species of the genus Leishmania
(1). More than 1.5 million people are affected by
these diseases each year in tropical, subtropical, and
Mediterranean regions of the world (2). There are
about 22 Leishmania species that cause various clinical
manifestations. Leishmaniasis can result in visceral,
cutaneous, or mucocutaneous infections according
to the species (2-5). Visceral leishmaniasis (VL) is
most commonly caused by the Leishmania donovani
complex, but L. amazonensis in Latin America and
L. tropica in the Middle East, Mediterranean, and
Central Anatolia regions can be causative agents
for VL. On the other hand, cutaneous leishmaniasis
caused by the L. tropica complex is mainly seen
in the Middle East, the Mediterranean, Africa,
India, and Asia (1-3,6,7). In Turkey, L. infantum,
transmitted by Phlebotomus (Larroussius) tobbi, P.
(Larroussius) syriacus, P. (Larroussius) neglectus,
and P. (Larroussius) perfiliewi, produces VL as
reported sporadically in the Aegean, Mediterranean,
and Central Anatolia regions. Although cutaneous
leishmaniasis is caused by L. tropica in southeastern
Anatolia and the Mediterranean regions by its
suspected vectors, P. (Paraphlebotomus) sergenti or
P. (Phlebotomus) papatasi, it has been also reported
from the Central Anatolia and Aegean regions (7-9).
The main treatment choice for leishmaniasis
is chemotherapy, mainly based on pentavalent
antimonials (10). However, these are extremely
toxic and cause serious side effects, and there is a
worldwide increasing frequency of chemoresistance
to antimonials (11). Recently, liposomal amphotericin
B (AmBisome) has been used as the first drug; it was
approved by the FDA for VL in immunocompetent
patients. However, data on this drug are limited.
Sodium stibogluconate (Pentostam) and meglumine
antimoniate (Glucantime) are 2 pentavalent antimony
drugs that are recommended for use in the treatment
of both VL and cutaneous leishmaniasis. Similarly,
these compounds have dose-dependent side effects
and toxicities including the elevation of amylase and
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lipase and electrocardiographic changes. In addition,
multiple painful injections are undesirable and
especially difficult to administer to children (12-14).
Furthermore, using a single drug or a formulation for
all forms of leishmaniasis is impossible at the present
time (15,16). These issues emphasize the urgent need
for affordable alternative drugs or implementation
against leishmaniasis.
Many studies have shown that hyperoxia and
hyperbaric oxygen (HBO) inhibit microbial growth
by inducing various microbial metabolic reactions
in bacteria, fungi, and parasites through increased
generation of reactive oxygen species or free radicals
(17-19). Thus, it is used adjunctively with surgery and
antibiotherapy. The antioxidant defense mechanisms
of parasites for protection from free radicals have not
developed very well. Therefore, these organisms are
very susceptible to HBO. Inducing oxidative stress
inhibits the growth of parasites. The actions of several
antiparasitic drugs also have effects on reducing the
levels of antioxidant enzymes in parasites (17,18,2022). There are a few studies reporting the efficiency
of HBO therapy for Leishmania amazonensis and
Leishmania braziliensis panamensis. These studies
concluded that HBO exposure was sufficient to reduce
promastigote growth and had an inhibitory effect on
the ability of transformation into amastigotes (23-25).
In the present study, we aimed to assess the efficiency
of HBO therapy on L. tropica, which is the major
causative agent of cutaneous leishmaniasis in Turkey.
Materials and methods
Parasite and culture procedures
L. tropica (MHOM/TR/05/EP117) promastigotes
were provided by the Department of Parasitology,
Ege University Medical Faculty, and cultured
at 24-26 °C in RPMI-1640 medium containing
10% fetal calf serum (FCS) (both products from
Biological Industries, Israel). At regular intervals, the
parasites were harvested in the log phase of growth.
Amastigotes were obtained from promastigotes using
primary mouse macrophage culture.
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Macrophage cultures and infection of macrophages
BALB/c female mice, 6 weeks old and weighing 2530 g, were used. The animals were supplied by the
Gülhane Military Medical Academy Research Center.
Macrophages were obtained from normal BALB/c
mice by peritoneal lavage. The peritoneal macrophages
were stimulated by injecting approximately 1 mL of
RPMI-1640 medium into the peritoneum and then
the macrophages were collected the following day.
The peritoneal exudates were washed with 5 mL of
RPMI-1640 and then centrifuged. The precipitated
peritoneal exudate was suspended in RPMI + 10%
FCS. The concentration was adjusted to provide
106 macrophages/mL. The macrophage-containing
medium was then transferred to 25-cm2 culture flasks
and allowed to incubate for 24 h at 37 °C under 5%
CO2. Following incubation, the macrophages were
infected with L. tropica promastigotes in the log phase
at a concentration of 10 promastigotes/macrophage.
HBO treatment
Promastigotes (106 parasites/mL), suspended in 5
mL of phenol red-free RPMI + 10% FCS, were placed
in 25-cm2 culture flasks. The parasites in the flasks
and infected macrophage monolayers in 24-well
culture plates were placed in a horizontal position in
the HBO chamber (ETC Monoplace Chamber, ETC
Biomedical Systems, USA). The pressure (PO2 253.3
kPa, 2.5 atmosphere absolute) was maintained for 2,
4, and 6 h, and then the chamber was decompressed
over a period of 5 min. The HBO treatment protocol
was planned at a level that could be tolerated by
humans. The antioxidant N-acetylcysteine (NAC) (30
mM) was used as a protective agent for promastigotes
exposed to HBO, and some cultures were treated for
90 min with NAC before the HBO treatment.
Evaluation of
promastigotes

HBO

effects

on

L.

tropica

The number of promastigotes and their morphology
were checked using a Neubauer hemocytometer. The
numbers of viable cells were counted using a trypan
blue dye exclusion test. The growth inhibition was
calculated using the following equation:
(Number of promastigotes in the control group
– number of promastigotes in the treated group)
/ number of promastigotes in the control group =
growth inhibition.

The cytotoxicity of the promastigotes was analyzed
using the colorimetric 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) dyereduction assay (Sigma, USA). Briefly, after 200 μL
of each parasite suspension exposed to HBO was
transferred to ELISA wells, the formation of formazan
was measured by adding MTT (2 mg/mL in phenol
red-free RPMI-1640, 100 μg/well) and incubating
the wells for 4 h in the dark at 37 °C. The wells were
centrifuged at 2000 rpm for 5 min and the supernatant
was removed, the pellet was dissolved by isopropanol,
and absorbances were measured at 490 nm (26).
The negative control well was used for baseline zero
absorbance (A). Results were presented as percentage
of cytotoxicity, determined as: (1 – A of experimental
well / A of positive control well) × 100. These
experiments were repeated following days 1, 2, and 3.
HBO effects on L. tropica amastigotes
Amastigote viability was determined by a modification
of the method of Channon et al. (27). Briefly, following
the final HBO incubation, the macrophages were
scraped out using a cell scraper (Sigma), and 50 μL
of cell suspension was incubated with a mixture of
acridine orange (5 μg/mL) and ethidium bromide (50
μg/mL) for 10 min at room temperature. The stained
smears were examined via fluorescence microscopy
(Zeiss 100 W/2, Carl Zeiss, Germany). To determine
the ratio of affected amastigotes, the average of 100
macrophages that contained amastigotes, either
live (green fluorescence) or dead (red-orange
fluorescence), was calculated.
Statistics
The results were expressed as the percentage of
dead cells. The Mann-Whitney U test was used to
compare each experimental group with the control.
The Friedman test was used for the comparison of
cytotoxic effects on different days. P < 0.05 was
considered statistically significant. All statistical
analyses were carried out using SPSS 11.0 for
Windows.
Results
Cytotoxicity and the growth inhibitory effect of
HBO treatment on L. tropica promastigotes
We investigated cytotoxicity and the growth
inhibitory effect of HBO treatment on L. tropica
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100
90
Percentage of viability (%)

promastigotes. After 2 h of HBO treatment, no
significant differences (P > 0.05) in the motility
and viability of the promastigotes were detected. A
significant difference was observed in the decreasing
of cell viability after 4 and 6 h (P < 0.001), as shown by
the trypan blue exclusion test (Figure 1). Moreover,
the motility of HBO treated promastigotes at 4 and
6 h of treatment became more circular. In contrast,
untreated promastigotes in the control group
remained 95% viable, highly motile, and spindleshaped (Figure 2). Pretreatment of the cells with the
antioxidant NAC (30 mM) prior to exposure could
completely abrogate the effect of HBO on motility
and cell viability. The cytotoxic effect of the increasing
O2 tension on L. tropica promastigotes was examined
separately on days 1, 2, and 3. The cytotoxic effect
that was observed on day 3 was 73.3%, and it was
significantly higher than those observed on previous
days (P > 0.05). It was observed that the metabolic
products of MTT were not formed in the control
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70
*

60
50

*

40
30
20
10
0
Hour 2

Hour 4

Hour 6

Control

A

B

C

D

Figure 2. The microscopic views of L. tropica promastigotes in culture, with and without HBO (control),
at 2, 4, and 6 h (40×): A) 2 h, B) 4 h, C) 6 h, and D) control. It was observed that L. tropica
promastigotes lost their motility and became more circular after exposure to HBO for 4 and
6 h. In contrast, untreated promastigotes in the control group remained 95% viable, highly
mobile, and spindle-shaped.

708

NAC

Figure 1. Cell viability was measured using the trypan blue
viability test. L. tropica promastigotes in culture, both
untreated (control) and pretreated with NAC, were
exposed to HBO for 2, 4, and 6 h. Cell viability rates
were expressed as a percentage of the untreated cells.
There was a significant difference between the treated
cells and the untreated cells (*P < 0.001). The data
depict the mean ± SD of 3 separate experiments.
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The effect of HBO on L. tropica amastigotes in the
macrophages obtained from BALB/c mice
The number of parasites was lower in the cultures
treated with HBO than in the untreated cultures
at 2 h of treatment. It was also observed that the
amastigotes died within the macrophages. Although
the total number of parasites decreased after 4 and 6 h
(P < 0.05), it was observed that the loss of amastigotes
in the HBO-treated macrophages was higher than
that of the control cells (Figure 5).
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Promastigotes (1 × 106/mL)

group or the promastigotes subjected to NAC. The
NAC protected the promastigotes against the effect
of the HBO. According to the MTT method, the
percentage of the cytotoxic effect of HBO on the
promastigotes compared to the control group is
shown in Figure 3. The promastigotes treated with
HBO were transferred to normal oxygen medium
(fresh medium) after 6 h to protect the cells from the
effect of the elevated partial oxygen pressure that was
dissolved in the medium. The numbers of the dead
and live promastigotes were counted microscopically
using the trypan blue exclusion test and were
calculated each day. While a slight elevation in the
number of live promastigotes was observed after 2 h
of incubation following the treatment, the elevation
in the number of cells was significantly suppressed
after 4 and 6 h of HBO treatment (P < 0.001). The
growth-inhibiting effect of HBO treatment on the
promastigotes is shown in Figure 4.

*
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Hours 4

*
Hours 6

Control

Figure 4. The effect of the growth inhibition of HBO exposure
on L. tropica promastigotes daily in culture and those
not exposed to HBO (control) at 2, 4, and 6 h. The
data depict the mean ± SD of 3 separate experiments.
Exposure to HBO for 4 and 6 h significantly suppressed
the elevated promastigote numbers (*P < 0.001).
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Figure 3. Cytotoxicity percentage of HBO exposure for L.
tropica promastigotes in culture, not exposed to HBO
(control) and pretreated with NAC on days 1, 2, and 3.
The data shown represent the mean ± SD of 3 separate
experiments. The significance of the difference
between the treated and untreated cells is indicated (*P
< 0.05).
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Figure 5. Comparison of HBO treatments on L. tropica
amastigotes in mice peritoneal macrophages with
the control macrophage culture cells (not exposed to
HBO) at 2, 4, and 6 h. The significance of the difference
between the treated and untreated cells is indicated (*P
< 0.01).
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Discussion
In the present study, the toxic effect of HBO on L.
tropica promastigote and amastigote forms was
demonstrated. The cytotoxic effect of HBO began 2 h
after treatment and reached a maximum level after 6 h
(54.2%) in the treated groups. The rate of HBO effect
on L. tropica amastigotes increased as time passed,
from 3.3% at 2 h to 38.5% at 6 h (Figure 5). The other
significant observation was that HBO-mediated
toxicity is irreversible even after 2 h of treatment.
Muhvich et al. examined the effect of HBO on
L. braziliensis panamensis and found that 90% of
the promastigotes died after 24 h of HBO treatment
(25). In our study, we detected that 54.2% of the
promastigotes died after 6 h and growth inhibition
was observed in most of the promastigotes. As is
widely known, a period of 24 h is quite a long time for
HBO treatment. Detection of inhibition in the growth
of promastigotes even after 2 h suggests that a shorter
duration of treatment may be clinically effective.
Arrais-Silva et al. (23) examined the effect of HBO
on L. amazonensis and obtained results consistent
with ours, yet our results were somewhat higher than
those obtained by Arrais-Silva et al. (23). The reason
for this is that we subjected the cell culture plaques to
a constant HBO treatment for a 3-day period without
replacing the fresh culture medium. We conducted
an MTT assay every day at 2, 4, and 6 h and recorded
the results. Of course, partially dissolved O2 may exist
within the cell culture plaques, so the effect may be
larger. As a result, we determined that the majority of
the promastigotes may die from a short duration of
HBO treatment, such as 2 h/day for 3 days. We also
observed that HBO treatment became influential for
the macrophage cells obtained from mice infected by
L. tropica amastigotes after 2 h of treatment, but when
this time was extended, the control macrophage cells
were also affected. We think that the effect of HBO
treatment on the amastigote forms in a short time,

2 h, was a remarkable advantage. In other studies,
it was also shown that the promastigote forms were
more sensitive to the treatment when compared
to the amastigote forms. The reason for this was
that the amastigote forms develop self-defense
mechanisms with antioxidant defense molecules like
glutathione peroxidase and intracellular thiol against
macrophage toxic oxidant products like hydrogen
peroxide (H2O2) and superoxide (O2-) (17,28-30).
Das et al. reported that H2O2 caused an apoptosis-like
death in L. donovani promastigotes (31). Obviously,
superoxide and hydrogen peroxide are the main
products formed by the HBO treatment. In our
study, it was also proven that the effect of the HBO
treatment was inhibited when used along with NAC,
which has an antioxidant property. However, as NAC
cannot overcome the reactive oxygen products under
an adequate pressure, it cannot prevent the inhibiting
effect of HBO on the growth of the promastigotes
(23). HBO treatment plays a great role in clinical
treatment, especially in the healing of wounds (32).
In conclusion, the cytotoxic effect of HBO
treatment on the L. tropica promastigote and
amastigote forms within the macrophages was
demonstrated in this study. Since the inhibitory effect
of the treatment on the growth of the promastigotes
occurred in a short time, 2 h, the dose and duration
of the application could be tolerated by humans,
and this method could be used for the treatment of
cutaneous leishmaniasis with chemotherapy. We
believe that further studies are needed for its more
reliable use in the treatment of human patients.
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